Alembic Pharma Gains USFDA Tentative Approval for Generic Larotrectinib as Sole First Applicant

Alembic Pharmaceuticals has secured a USFDA tentative approval for its generic version of Larotrectinib capsules, positioning the company as the sole first applicant for Bayer's Vitrakvi, a status that carries eligibility for 180-day generic exclusivity once final approval conditions are met.

Larotrectinib is a TRK inhibitor indicated for adult and pediatric patients with solid tumors harboring NTRK gene fusions. Vitrakvi, marketed by Bayer, holds reference listed drug status in the U.S. market. Tentative approval under 21 CFR Part 314 confirms that Alembic's ANDA has met bioequivalence, labeling, and chemistry, manufacturing, and controls requirements, but final approval is withheld pending expiration of applicable patents or exclusivities on the reference product.

For regulatory affairs leads tracking oncology ANDA strategy, the sole first-applicant designation is the operative detail. Under Hatch-Waxman provisions, a single first applicant retains the full 180-day exclusivity window without the dilution that occurs when multiple applicants share the designation. That window, once triggered, directly compresses Bayer's branded market share before any subsequent generic entrant can launch.

From a manufacturing and quality standpoint, tentative approval signals that Alembic's facility and process submissions have cleared FDA's pre-approval review threshold. Plant heads overseeing oncology solid-dose lines should note that maintaining GMP compliance through the exclusivity period is non-negotiable, any Form 483 observation or warning letter issued before final approval converts could delay or forfeit the exclusivity position entirely.

Alembic has been systematically expanding its oncology generics pipeline in the U.S., and this ANDA reflects a deliberate first-to-file posture in a specialty segment where branded pricing remains elevated and generic penetration has historically been slow to materialize.

The 180-day exclusivity clock will start upon the first commercial marketing of the product, contingent on final approval, a checkpoint that QA and regulatory teams at Alembic will need to manage against the patent expiry timeline for Vitrakvi.

Source: Media4Growth via Indian Pharma Post, 10 June 2026.